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Objective. To evaluate the safety and survival in women treated with adjuvant pelvic radiation “sand-
wiched” between six cycles of paclitaxel and carboplatin chemotherapy with completely resected UPSC.
Methods. Surgically staged women with UPSC (FIGO stage 1–4) and no visible residual disease were en-
rolled. Treatment involved paclitaxel (175 mg/m2) and carboplatin (AUC=6.0–7.5) every 21 days for 3
doses, followed by radiation therapy (RT), followed by an additional 3 cycles of paclitaxel and carbopla-
tin (AUC=5–6). Survival analysis, using Kaplan–Meiermethods, was performed on patients who completed at
least 3 cycles of chemotherapy and RT.
Results. A total of 81 patients were enrolled, of which 72 patients completed the ﬁrst 3 cycles of chemother-
apy followed by prescribed RT. Median age was 67 years (range: 43–82 years). 59/72 (82%) had disease con-
ﬁned to the uterus and 13/72 (18%) had completely resected extra-uterine disease (stage 3 and 4). 65 (83%)
completed the protocol. Overall PFS and OS for combined stage 1 and 2 patients was 65.5±3.6 months and
76.5±4.3 months, respectively. PFS and OS for combined stage 3 and 4 patients was 25.8±3.0 and 35.9±
5.3 months, respectively. Three-year % survival probability for stage 1 and 2 patients was 84% and for stage 3
and 4 patients was 50%. Of the 435 chemotherapy cycles administered, there were 11(2.5%) G3/G4 non-
hematologic toxicities. 26(6.0%) cycles had dose reductions and 37(8.5%) had dose delays.
Conclusions. Compared to prior studies of singlemodality adjuvant therapy, RT “sandwiched” betweenpaclitax-
el and carboplatin chemotherapy iswell-tolerated and highly efﬁcacious inwomenwith completely resected UPSC.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Among the other non-endometrioid subtypes of endometrial cancer,
uterine papillary serous carcinoma (UPSC) is the most common. Al-
though UPSC constitutes approximately 10% of endometrial cancers, it
accounts for a disproportionate amount of all endometrial cancer deaths
[1]. It is an aggressive epithelial endometrial cancer subtype and is
often diagnosed at an advanced stage. Recurrence of UPSC, particularly
extra-pelvic recurrence, is common and difﬁcult to control. PelvicAlbert Einstein Cancer Center
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ncology, 1695 Eastchester Rd.,
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tein).
NC-ND license.radiation decreases the risk of pelvic recurrence in UPSC, but has not
been shown to improve overall survival secondary to extra-pelvic recur-
rences and distant metastasis [2].
Due to the systemic nature of UPSC, there have been a number of
studies sequentially combining pelvic radiation therapy (RT) for local
control, in addition to chemotherapy for systemic control. Combining
whole abdominal radiation (WAR) with platinum containing regimens
has shown promise with improved survival in patients who had
measurable disease following primary surgery [3]. This was followed
by a number of reports of sequential use of paclitaxel and carboplatin
followed by pelvic radiation in patients with advanced endometrial
cancer (stage 3 and 4withmeasurable disease after surgery), including
some patients with UPSC [4–7]. In these studies, in a treatment and not
adjuvant setting, the toxicity proﬁlewas acceptablewithminimal pelvic
recurrences and improved survival.
In a multi-institutional retrospective analysis of 356 patients with
stages 3 and 4 endometrial cancer, of which 86 women had UPSC, inves-
tigators compared outcomes in patients who received either RT alone,
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RT. In this analysis, patients receiving chemotherapy alone had poorer
3-year OS and PFS compared to either RT alone or combination therapy.
Also, adjuvant chemotherapy and RT was associated with improved
survival in patients with advanced stage disease compared to either
modality alone,with little difference in the toxicity proﬁle ofmultimodal
therapies [8].These ﬁndings were conﬁrmed in another retrospective
study that included patients treated with various therapies, including
sequential chemotherapy and radiation therapy. In this analysis, pa-
tients who had stage II UPSC who were treated with chemotherapy
had a favorable PFS when compared to patients who did not receive
chemotherapy [9].
Because of the success of combined sequential chemotherapy and
RT treatments for advanced uterine cancers, including UPSC, with
measurable disease after primary surgery, a number of groups have
evaluated the recurrence and survival patterns of patients undergoing
adjuvant treatment for UPSC with no visible disease after surgery. A
phase II GOG study by Sutton et al. evaluated the role of adjuvant
WAR in 21 patients with stages I and II UPSC and clear cell uterine
carcinomas [10]. In this study the authors concluded that other adjuvant
approaches such as chemotherapy in combination with RT should be
considered. Obermair and colleagues conducted a multi-center, pro-
spective, non-randomized phase II clinical trial in women with early
stage UPSC and clear cell carcinoma using 4 cycles of paclitaxel plus
carboplatin followed by pelvic RT to evaluate the tolerability and
safety of sequential therapy in these patients. The 2-year overall survival
was 86% with stage 1 and 2 disease and 69% with stage 3 and 4 disease
[7].
Our group performed and reported our pilot data of adjuvant
sequential chemotherapy with radiation therapy in a “sandwich”
fashion [11]. The “sandwich” strategy hypothetically allows for control
of systemic diseasewith chemotherapywhile treatingmicro-metastasis
in the pelvis with RT. Furthermore, the sequential delivery of chemo-
therapy and RT limits the overall toxicity and allows for maximum
therapeutic dosing for both the chemotherapy and the RT. In our
pilot study, we found improved survival, particularly in advanced stage
patients, with acceptable toxicity in the ﬁrst 30 women who received
the “sandwich” therapy. As a result of these pilot data, we performed a
non-randomized phase II prospective trial of radiation “sandwiched”
between paclitaxel/platinumchemotherapy for patientswith completely
resected UPSC [11].
Materials and methods
After IRB approval, eligible patients were recruited from 1999 to
2009 to this registered phase II trial (clinicaltrials.gov identiﬁer:
NCT00231868). In addition to newly-recruited patients, this analysis
also includes subjects that were treated with carboplatin and paclitaxel
with RT in the same fashionwith updated follow-up fromour previously
reported pilot data [11]. During this pilot phasewe optimized the carbo-
platin dosing, speciﬁcally due to the additional toxicity often seen after
RT with the higher carboplatin doses. After optimization, our standard
dosing for the trial led to a carboplatin dose at an AUC of 6 before and
an AUC of 5 after RT.
After IRB approval and clinical trials registration, eligible patients
were recruited over a 10 year period at Monteﬁore Medical Center
and Albert Einstein College of Medicine. Eligible patients included
histologically documented UPSC (updated FIGO stage 1–4) with no
visible residual disease after surgery. All FIGO stage 1 patients had
residual disease in the hysterectomy specimen. All eligible subjects
underwent surgical staging, which included a hysterectomy, bilateral
salpingo-oophorectomy, pelvic and para-aortic lymph node sampling
and peritoneal washings. Infracolic omentectomy was preferred, espe-
cially for the stage IV recruited subjects who had omental metastases,
but this was not required in patients without visible omental disease.
All eligible subjects had an ECOG performance status of 0 or 1, adequatehematologic function (hematocrit≥30%, WBC≥300/mm3, platelet
count≥100,000/mm3), BUN≤25mg%, creatinine≤2 mg%, total biliru-
bin≤1.5 mg/dl, aminotransferases≤2.5 times the institutional upper
limit of normal. Patients with signiﬁcant concurrent medical conditions
limiting their life expectancy to≤3 months or those who received prior
chemotherapy and/or RT for pelvic malignancy, were excluded.
At screening, all patients had protocol-required lab testing, including
tumor markers, EKG, chest X-ray, and CT scan of the chest, abdomen,
and pelvis. In addition to a physical examination, complete blood
counts, serum electrolytes, and markers were performed prior to each
cycle of chemotherapy and after completion of chemotherapy, every
3 months for 24 months, and then every 6 months thereafter. Imaging
was repeated after treatment and during follow-up as clinically indicat-
ed. Adverse events were monitored for each cycle during therapy and
during follow-up and graded using the National Cancer Institute Com-
mon Toxicity Criteria, version 3.0 as this study began prior to instituting
NCI CTC v4.0.
Treatment
Chemotherapy
Registration and screening for the protocol was initiated within
6 weeks after surgery. Paclitaxel was administered at a dose of
175 mg/m2 over 3 h. During the pilot phase and the beginning of
the registration trial, the carboplatin doses were adjusted to minimize
hematologic toxicity, while maintaining therapeutic doses. Chemo-
therapy was administrated every 21 days for 3 cycles prior to RT; then
an additional 3 cycles every 21 days were administered after RT. Over
half of the patients (52.2%) were administered the 4th cycle (1st cycle
after RT) the same week as the brachytherapy. Standard premedica-
tions to minimize hypersensitivity and nausea for paclitaxel and carbo-
platin were administered.
Prior to each subsequent cycle of therapy, patients were required
to have recovered to an ANC≥1500/mm3 orWBC≥3000/mm3, plate-
lets≥100,000/mm3 and renal and hepatic parameters the same as for
screening. Treatment modiﬁcations for hematologic toxicities included
cycle delay until recovery with subsequent dose reduction, in addi-
tion to the addition of G-CSF and/or erythropoietin according to
provider preference. All toxicities, dose delays, and dose reductions
were recorded.
Radiation therapy
Radiation therapy began one week after the 3rd cycle of chemo-
therapy. The total dose of external beam pelvic radiation therapy
(EBRT) was 45 Gy over 5 weeks. Patients were treated once per day,
5 days per week, with a daily fraction size of 1.8 Gy. A four-ﬁeld con-
formal radiation therapy technique (AP-PA opposed and lateral opposed
ﬁelds) or intensity modulated radiation therapy (IMRT) was used with a
megavoltage beam of ≥6MV. The ﬁelds were extended to include the
para-aortic nodal region in the case of≥2 positive pelvic nodes or docu-
mented para-aortic lymph node disease, with positive lymph nodes
marked with hemoclips at the time of surgery.
In 63 of the 72 patients who had chemotherapy and RT, high dose
rate (HDR) brachytherapy via vaginal cylinder was used to boost the
dose to the proximal 1/2–2/3rds of the vagina. Segmented cylinders
of the largest size that would be accommodated by the vagina were
used. Three fractions of 5 Gy each prescribed to 0.5 cm depth from
the vaginal surface were given once per week using the Nucletron
microSelectron HDR Ir-192 remote afterloading technique.
Statistical considerations
The accrual of additional evaluable subjects in addition to the
original pilot patients was to further evaluate toxicity, extend survival
Table 1
Patient characteristics.
Number Percent
Race
Black 42 54
White 32 41
Asian 2 2.5
Other 2 2.5
Ethnicity
Hispanic 15 19
Non-Hispanic 63 81
FIGO Stage
Total Stage I 56 72
IA 45 58
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formed on the 72 patients who had at least 3 cycles of chemotherapy
and had any amount of prescribed RT.
Response was evaluated using an end point of 3-year progression-
free survival. Disease-free survival (DFS) was calculated from the date
of study registration to date of recurrence. Overall survival (OS) was
calculated from the date of registration until the date of death or
the date of last visit. Disease-free survival and overall survival curves
were constructed using the Kaplan–Meier (KM) method. Site and
date of recurrence were recorded, and conﬁrmed by histology and/or
cytology when possible. For added power, stage 1 and 2, or early-stage
patients, were combined aswell as stage 3 and 4 patients with complete-
ly resectedmetastatic disease. Frequencies for toxicity and adverse events
were also recorded and tabulated.IB 11 14
Total Stage II 8 10
Total Stage III 11 14
IIIA 1 1
IIIB 0 0
IIIC1 6 8
IIIC2 4 5
Total Stage IV 3 4
IVA 0 0
IVB 3 4Results
A total of 81 patients were enrolled and 72 evaluable patients
were included in this analysis (see Fig. 1). Three subjects did not
proceed with the prescribed regimen after registration. Of the 78
subjects who proceeded with the protocol-prescribed regimen, 72
patients completed the ﬁrst 3 cycles of chemotherapy followed by
RT. Of the 72, 67 patients completed the prescribed RT (63 had
EBRT+brachytherapy and 9 had EBRT alone). Of the 67 patients
who completed the ﬁrst 3 cycles of chemotherapy and prescribed
RT, 65 (97%) completed the last 3 cycles of paclitaxel and carboplatin.
The carboplatin doses for the 72 subjects who received carboplatin
before RT was as follows: carboplatin at an AUC of 7.5 (n=20), 6.5
(n=20), 6 (n=24), under 6 (n=14). Of the 65 who received che-
motherapy after RT, the carboplatin doses were 6.5 (n=14), 6.0
(n=14), 5.0 (n=37), under 5 (n=2).
Thepatient demographics and stage are in Table 1. This is an ethnically
and racially diverse referral population fromBronx, NY and the surround-
ing communities. Themean age of thepatientswas 67±7.9 (mean±SD).
Themean BMI of the patients was 30.7±6.35 (mean±SD). All of the
advanced staged patients underwent omental sampling (omentectomy
or biopsy) and 37/59 (63%) of the early stage patients underwent
omental sampling.81 patients enrolled
3 did not proceed with prescribed 
regimen after registration
78 patients initiated therapy
6 did not proceed with prescribed RT
72 patients completed the first 3 cycles          
of chemotherapy followed by RT
5 did not complete prescribed RT
67 patients completed prescribed RT  
(63 had EBRT+Brachytherapy, 9 had EBRT alone)
2 did not complete last 3 cycles of T/C
65 patients completed full prescribed therapy
Fig. 1. Treatment numbers on protocol. Toxicity analysis performed on the 78 patients
who received at least one dose of chemotherapy. Survival analysis was performed
in all patients who received the ﬁrst 3 cycles of chemotherapy followed by RT.Survival
All evaluable patients had a minimum follow-up of 9 months after
completion of therapy. Four patients were lost to follow-up after at
least 16 months from initiation of treatment and their survival status
was censored after the date of last follow-up. Fig. 2 shows the overall
survival probability dichotomized to early stage (stage 1 and 2) or
advanced stage (stage 3 and 4) patients. 13/59 (22.0%) early stage
patients recurred and 7/13 (53.8%) advanced stage patients recurred
during this study period. In the 72 patients who received at least 3
cycles of chemotherapy and EBRT, the overall PFS and OS for early
stage patients was 65.5±3.6 (mean±standard error) months and
76.5±4.3 months, respectively. PFS and OS for patients with advanced
stage was 25.8±3.0 and 35.9±5.3 months, respectively. Three-year %
survival probability for early stage was 84% and advanced stage was
50%, respectively. Of the 65 patients who completed all 3 cycles ofFig. 2. Kaplan-Meier overall survival curve of early stage (stage 1 and 2) and late stage
(stage 3 and 4) UPSC patients who were prescribed radiation “sandwiched” between
three cycles of paclitaxel/platinum chemotherapy before and after RT. In the 72 patients
who received at least 3 cycles of chemotherapy and EBRT, overall PFS and OS for early
stage patients was 65.5±3.6 (mean±standard error) months and 76.5±4.3 months,
respectively. PFS and OS for advanced stage patients was 25.8±3.0 and 35.9±
5.3 months, respectively. Three-year % survival probability for early stage patients
was 84% and for advanced stage patients was 50%.
Table 3
Number of dose reduction and delays by cycle (n=435 total cycles).
Cycle Number # of reductions # of delays
1 0 2
2 4 5
4 4 4
4 3 5
5 5 9
6 10 12
Total 26 (6.0%) 37 (8.5%)
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more cycles of chemotherapy, The three-year % survival probability
for early stage patients was 85% and advanced stage patients was
62%, respectively.
There were no patterns or preferential region for recurrence. Of
the 20 patients who recurred, 4/20 (20%) recurred in the radiated
ﬁeld and 16/20 (80%) recurred outside the radiated ﬁeld. Three are
still alive with disease getting additional treatment. Of those who
died, all but one died of their recurrent cancer. The mean time from
disease recurrence to death was 29±11.7 months. There were no
treatment related deaths.
Toxicity
Table 2 is a summary of the hematologic and non-hematologic
toxicities. A total of 435 cycles of paclitaxel/carboplatin were admin-
istered on protocol from which frequencies of hematologic and non-
hematologic toxicities were tabulated. There were no signiﬁcant
differences in the frequencies of toxicities of the higher doses of
carboplatin used in the minority of subjects during the pilot phase, so
the toxicities were combined for analysis. Of note, 71/118 (60.2%)
grade 3 and grade 4 toxicities occurred after RT resulting in themajority
of dose reductions and/or dose delays (44/62 or 71%; see Table 3). The
majority were self-limiting hematologic toxicities and in most cases it
was the provider preference to administer growth factor support
in subsequent cycles after a grade 3 or 4 hematologic toxicity. There
were no patterns of increased long term toxicity attributable to radiation
therapy with this regimen.
Discussion
In this large prospective study of womenwith completely resected
UPSC, RT “sandwiched” between paclitaxel/carboplatin chemotherapy
is well-tolerated and highly efﬁcacious, when compared to prior studies
of single modality adjuvant treatment for UPSC, including in treated
patients with advanced stage disease. The toxicities were acceptable
and predictably more common following the RT with the vast majority
being self-limiting and managed conservatively. These results show
additional long term survival and considerably more prospectively
tracked efﬁcacy and toxicity data fromour prior pilot report [11]. Patients
with both early and advanced stage UPSC who are treated with this
“sandwich” protocol have excellent survival, with a 3 year survival prob-
ability of 84% in early stage patients and 50% in advanced stage patients.
Even better survival was noted among patients who completed all of
the prescribed therapy, 85% in early stage patients and 62% in advanced
stage patients. These results compare favorably with prior reports in
treatments of UPSC.Table 2
Summary of Grade 3 and 4 hematologic and non-hematologic toxicities (n=435 total
cycles).
Grade 3 Grade 4
Hematologic Toxicities
Neutropenia 27 44
Anemia 11 2
Thrombocytopenia 24 10
Total 62 (14.3%) 56 (12.9%)
Non-Hematologic Toxicities
Infection (e.g. urinary) 5 0
Deep vein thrombosis 2
Neuropathy 2 2
Electolyte abnormality 1 0
Dehydration 1
Hypertension 0 1
Small bowel obstruction 0 1
Total 12 (2.8%) 4 (0.9%)There is a lack of consensus regarding the standard management of
womenwith UPSC.Most treatments for UPSC appear to involve adjuvant
therapy that includes chemotherapy, RT, or both [4–6,8,12]. However
most of the prior reports lack the size, power, or prospective data collec-
tion to effectively evaluate the true effect size. To our knowledge, this is
the largest prospective trial for this rare tumor, and our survival exceeds
most prior reports and obviates the added toxicity of this combination
regimen. This protocol was well tolerated with generally self-limiting
toxicities and limited dose reductions and dose delays.
Despite the fact that this was a prospective trial, there are limitations.
The minor differences in the carboplatin dosing regimens during the
pilot phase may raise criticism. The carboplatin dose was optimized
during the pilot phase, but all doses were within the therapeutic
window for carboplatin. After further optimization during the early
part of the pilot and registration phase, the prescribed dose regimen
remained consistent. Homogeneity between the groups was conﬁrmed
by Cox-regression matched analysis regarding toxic events, recurrence,
and survival. Also, this is a single institution trial, with the potential for
all biases attributed to any single institution study. However, we believe
this is a strength of this study, as well, as most of the investigators were
actively working together during this whole trial period and became
comfortable with the treatment and managing the toxicity. Also, all
subjects who met criteria were approached to register. Only 63% of
the early stage patients underwent omental sampling. However, if
any of the remaining early stage patients had been misclassiﬁed as
being understaged as a result of lack of an omentectomy, this would
only improve our efﬁcacy results in misclassiﬁed early stage patients
as they would have been upstaged to stage 4, which would improve
the advanced stage survival evenmore. Additionally, we accrued a lim-
ited number (n=14) advanced stage patients to this protocol. This is
primarily due to the fact that most patients with metastatic UPSC
have measurable disease even after staging surgery. The survival in
the patients on this protocol cannot be extrapolated to stage 3 and 4
UPSC patients with measurable disease after surgery.
While the sequencing of the chemotherapy and radiation therapy
in this protocol was 3 cycles prior to RT, then 3 cycles after RT, this
might not be the optimal sequence for a “sandwich” therapy. It should
be noted that the vast majority of patients (65/67) who received 3
doses of chemotherapy followed by EBRT, were able to complete the
remaining three cycles of chemotherapy. The additional three cycles
of chemotherapy after RT is well-tolerated. Also, in the subset of 65
patients who completed all cycles of chemotherapy and RT there
was a slightly higher survival, though not statistically signiﬁcant.
Another “sandwich” method of sequential adjuvant chemotherapy
and radiation was further investigated by Geller et al. in advanced
stage endometrial cancer [4]. This was a retrospective analysis of 23
patients with advanced stage III or IV endometrial cancer, including 12
(52%) of the patients with UPSC, who received adjuvant chemotherapy
consisting of carboplatin and a taxane, with total number of chemother-
apy cycles prescribed ranging from 4 to 6, with at least 2 cycles post-
radiation. Of the 23 patients, 5 progressed and 3 of these patients died
during follow-up. The estimated 1, 3, and 5 year PFS was 100%, 80%,
and 74% respectively. This is comparable to the study by Obermair and
colleagues who used 4 cycles of paclitaxel plus carboplatin followed by
pelvic RT [7]. Further studies on the optimal sequencing in an adjuvant
25M.H. Einstein et al. / Gynecologic Oncology 124 (2012) 21–25setting in patients with UPSC are warranted. Until other sequences are
tested, through, this “sandwich” therapy should be considered and po-
tentially conﬁrmed as a treatment arm in future cooperative group trials.
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